Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

3 clinical trials; the ability of the Natural History Staggered Start trial design and trial analysis methodology to provide the same level of disease modification support as the cross-over trial designs; the ability of the Natural History Staggered Start trial design and trial analysis methodology to demonstrate that this trial analysis methodology is mathematically equivalent to the "Staggered Start" and "Randomized Withdrawal" designs and provides the same level of evidence of a disease modifying drug effect in a clinical trial that is not subject to the complications, bias and ethical challenges of previous designs; the excitement of the Company about this persuasive mathematical comparison of clinical trial designs and the Company's belief that this mathematical proof, coupled with the Flurizan trial design, may strengthen the Company's position with the FDA in favor of a disease modification label for Flurizan; the successful completion of the ongoing Flurizan Phase 3 trials; and whether the Flurizan Phase 3 trials results will demonstrate or support a claim of disease modification. These forward-looking statements are based on management's current expectation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements. These include, but are not limited to, uncertainties as to the extent of future government regulation of Myriad Genetics' business; uncertainties as to whether Myriad Genetics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutic compounds; the risk that markets will not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to sell compounds, which it develops, at acceptable prices; and the risk that the Company will not be able to sustain revenue growth for its predictive medicine busine
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference

Post Your Comments:
(Date:11/25/2009)...IDGE, N.J., Nov. 25 Regado Bioscie...ment of antithrombotic aptamers with active contro... President, will be presenting at the Piper Jaffra...rk Palace Hotel in New York City. Dr. Mazzo,s pre..., December 1 and will include an overview of the C...
(Date:11/25/2009)... Calif., Nov. 25 Abaxis,... manufacturing point-of-care blood analysis system...nd chief executive officer, will present at the 21...Wednesday, December 2, 2009 at 2:00 p.m. ET. The c...l in New York City. ,, About Abaxis ,, Ab...
(Date:11/25/2009)... HILL, N.C., Nov. 25 Cempra Pharma...rnandes, president and chief executive officer, wi... Care Conference at 8:50 a.m. EST, December 1, 200... Dr. Fernandes will provide an overview of the com...r the treatment of drug-resistant pathogens includ...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Versus Technology Inc Announces Sale of Real Time Location System to the St Louis VA Medical Center 51059 1Versus Technology Inc Announces Sale of Real Time Location System to the St Louis VA Medical Center 51059 2Versus Technology Inc Announces Sale of Real Time Location System to the St Louis VA Medical Center 51059 3Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 1Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 2Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 3Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 4For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 1For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 3
(Date:11/29/2009)... Traditional healthcare,s uncertain future and ris...rnative care. Affordable Acupuncture Scottsdale an... November 29, 2009 -- Affordable Acupuncture, LLC ...nd has been met with enthusiasm and gratitude. Its...tributed to two things, need and cost. "As f...
(Date:11/28/2009)...v. 28 Get ready for advanced vi...cal routine when Siemens introduces syngo. ...ual Meeting of the Radiological Society of North A...Cormick Place (Booth #825, East Building/Lakeside ..., Siemens, new imaging software for multimodalit...
(Date:11/28/2009)...n believed to affect circadian rhythm, , ...search suggests that an internal body clock that g...ent of bipolar disorder in children. , The fin...akeup of 152 children with bipolar disorder, which... and 140 children without the disorder. They linke...
(Date:11/27/2009)...s., Nov. 27 GSI Group In... of precision technology products and semiconducto...of the Company,s shareholders has been scheduled f...of the meeting will be announced in due course. A...uisition notice from Stephen Bershad, a holder of ...
(Date:11/27/2009)... Biotech firm Replikins Ltd. today issued its late...data. It shows that the lethality of the virus ha...he virus,s current outbreak in the spring of 2009 ....d. 0.1). The H1N1 infectivity count, however, rem...(PRWEB) November 27, 2009 -- Biotech firm Replikin...
Breaking Medicine News(10 mins):Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5
...on Remicade (infliximab) showed rapid, significant...laque psoriasis. The stud mainly used placebo-// c...The continuous eight week maintenance therapy resu...ients treated with Remicade 3 mg/kg and 75 % of pa...
...rn consumers on how to spot the misleading promoti...d nutritional HGH products.// Various spray ...uct manufacturers, distributors, or resellers are ...), representing 17,500 physicians in 86 nations wo...
... polyunsaturated fatty acids it has been revealed ...ealth benefits. // They influence mood, persona... study presented by University of Pittsburgh Schoo...olunteers. The researchers found that participants...
...sionals Follow-up Study has gathered data on men's...d questions on sexuality in 2000 to what is a semi...vard Men’s Health Watch says that there are some u... followed by chronic illnesses such as diabetes, h...
...the protective clothing to astronauts going to spa...forming as the basis to design// protective clothi... work in extreme heat and dangerous circumstances....kin to space suits used by astronauts. According t...
... kidnapped a couple’s 26 day old baby from a Strog...g to authorities//. The woman is now in police cus...ated kidnapping had appeared before Judge Raymond ...y fled the scene with the baby. The police ...
Other Medicine News:Health News:Beware Of Bogus Claims by HGH Spray Internet Marketers 2Health News:Beware Of Bogus Claims by HGH Spray Internet Marketers 3
IDS Rapid SS/u
Versatrek 240
ELP 40
96 PW Microplate Washer
Medicine Products: